Golgi phosphoprotein 3 sensitizes the tumour suppression effect of gefitinib on gliomas.

Xu WangZhaohao WangYu ZhangYan WangHao ZhangShao XiePeng XieRutong YuXiu-Ping Zhou

Published in: Cell proliferation (2019)

Our results demonstrate that GOLPH3 increases the sensitivity of glioma cells to gefitinib. Our study provides foundation for further exploring whether GOLPH3 high gliomas will be more sensitive to anti-EGFR therapy in clinic and give ideas for developing new possible treatments for individual glioma patients.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
end stage renal disease
high grade
newly diagnosed
ejection fraction
chronic kidney disease
primary care
peritoneal dialysis
prognostic factors
stem cells
mesenchymal stem cells
bone marrow
cell therapy